NIO752

DRUG4 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals, University College, London

Conditions

Alzheimer DiseaseAutosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)Mild Cognitive ImpairmentParticipants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Phase 1

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Active, not recruitingNCT05469360

Novartis PharmaceuticalsAlzheimer Disease, Mild Cognitive Impairment

Start: 2023-02-23End: 2027-09-24Updated: 2026-06-01

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

RecruitingNCT06372821

University College, LondonAlzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) +1

Start: 2024-11-18End: 2026-07-01Target: 10Updated: 2026-01-27

Phase 3

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

RecruitingNCT07498426

Novartis PharmaceuticalsProgressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Start: 2026-06-03End: 2031-07-18Target: 300Updated: 2026-07-29

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

Not yet recruitingCTIS2025-523481-24-00

Novartis Pharma AGParticipants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Target: 18Updated: 2026-04-22